Abstract Background: Cystic fibrosis (CF) is a genetic disease in which thick, sticky mucus is produced in the lungs (and other organs) that impairs ciliary clearance, leading to respiratory problems, increased chronic bacterial infections, and decreased lung function. Staphylococcus aureus is one of the primary bacterial pathogens colonizing the lungs of CF patients. This study aimed to characterize the genetic relatedness of S. aureus, its presence in children with CF, and its cytotoxic activity in THP1 cell-derived macrophages (THP1m) Methods: Genetic relatedness of S. aureus isolates from a cohort of 50 children with CF was determined by pulsed-field gel electrophoresis (PFGE). The VITEK® 2 automated system was used to determine antimicrobial susceptibility, and methicillin-resistance S. aureus (MRSA) was determined by diffusion testing using cefoxitin disk. The presence of mecA and lukPV genes was determined by the polymerase chain reaction and cytotoxic activity of S. aureus on THP1m by CytoTox 96® assay Results: From 51 S. aureus isolates from 50 children with CF, we identified 34 pulsotypes by PFGE. Of the 50 children, 12 (24%) were colonized by more than one pulsotype, and 5/34 identified pulsotypes (14.7%) were shared between unrelated children. In addition, 3/34 pulsotypes (8.8%) were multidrug-resistant (MDR), and 2/34 (5.9%) were MRSA. Notably, 30/34 pulsotypes (88.2%) exhibited cytotoxicity on THP1m cells and 14/34 (41.2%) altered THP1m monolayers. No isolate carried the lukPV gene Conclusions: Although a low frequency of MRSA and MDR was found among clinical isolates, most of the S. aureus pulsotypes identified were cytotoxic on THP1m.

Resumen Introducción: La fibrosis quística (FQ) es una enfermedad genética en la que se produce moco espeso y pegajoso en los pulmones (y otros órganos), lo que conduce a problemas respiratorios, incremento de las infecciones bacterianas crónicas y disminución de la función pulmonar. Staphylococcus aureus es uno de los principales patógenos que colonizan los pulmones de los pacientes con FQ. El objetivo de este trabajo fue caracterizar la relación genética de S. aureus, su presencia en niños con FQ y su actividad citotóxica en macrófagos derivados de células THP1 (THP1m) Métodos: La relación genética de los aislados de S. aureus provenientes de una cohorte de 50 pacientes con FQ fue determinada por electroforesis en gel de campo pulsado (PFGE). La sensibilidad a los antimicrobianos se determinó mediante el sistema automatizado VITEK® 2, y la resistencia a la meticilina (SARM) mediante la prueba de difusión utilizando discos de cefoxitina. La presencia de los genes mecA y lukPV se determinó mediante reacción en cadena de la polimerasa, y la actividad citotóxica de S. aureus sobre células THP1m mediante el ensayo CytoTox96® Resultados: A partir de 51 aislados de S. aureus provenientes de 50 niños con FQ se identificaron 34 pulsotipos por PFGE. De los 50 niños, 12 (24%) estaban colonizados por más de un pulsotipo y 5 de los 34 pulsotipos (14.7%) los compartían niños que no estaban relacionados. De los 34 pulsotipos, 3 (8.8%) presentaron multirresistencia (MDR) y 2 (5.9%) fueron SARM. Además, 30 pulsotipos (88.2%) fueron citotóxicos sobre células THP1m y 14 (41.2%) alteraron su monocapa. Ninguno de los pulsotipos presentó el gen lukPV Conclusiones: Aunque se encontró una baja frecuencia de SARM y MDR en los aislados, la mayoría de los pulsotipos de S. aureus identificados fueron citotóxicos para células THP1m.

Abstract The World Health Organization estimates that bacterial resistance will cause 10 million deaths by 2050. As part of the Global Action Plan on Antimicrobial Resistance, it proposed networks of specialized laboratories in order to preserve strains and optimize the use of antimicrobials. In a 2019 study, the main bacteria of the ESKAPE group (which are highly-resistant to the most widely used antibiotics) that cause infections in Mexican hospitals were identified to be multidrug-resistant (MDR) and extended spectrum beta-lactamase (ESBL)-producing Klebsiella spp., ESBL-producing Enterobacter spp., Acinetobacter baumannii, MDR Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. With information on drug resistance, regimens are recommended to treat infection caused by Helicobacter pylori, a pathogen related to the development of cancer and whose prevalence in the adult population of Latin America is estimated to range between 60 and 70%.

Resumen La Organización Mundial de la Salud estima que en 2050 la resistencia bacteriana ocasionará 10 millones de muertes. Como parte del Plan de Acción Mundial sobre la Resistencia a los Antimicrobianos propuso redes de laboratorios especializados, para conservar cepas y optimizar el uso de los antimicrobianos. En un estudio de 2019 se identificó que las principales bacterias del grupo ESKAPE (con alta resistencia a los antibióticos más usados) que causan infecciones en hospitales de México son Klebsiella spp. resistentes a múltiples fármacos (MDR) y productoras de betalactamasa de espectro extendido (BLEE), Enterobacter spp. BLEE, Acinetobacter baumannii, Pseudomonas aeruginosa MDR, Staphylococcus aureus meticilinorresistente y Enterococcus faecium resistente a vancomicina. Con la información de resistencia a los fármacos se recomiendan esquemas para tratar la infección causada por Helicobacter pylori, relacionado con el desarrollo de cáncer y cuya prevalencia en la población adulta de Latinoamérica se estima es de entre 60 y 70 %.

Objective. To assess the risks factors for urinary tract infections (UTIs) caused by Extended-Spectrum Beta-Lactamases (ESBLs)-producing E. coli and the molecular characterization of ESBLs. Materials and methods. A case-control study was performed to identify risk factors in consecutively recruited patients with UTIs caused by ESBLs or non-ESBLs-producing E. coli in a tertiary hospital in Mexico. Results. ESBLs-producing E. coli were isolated from 22/70 (31%) patients with E. coli UTIs over a three month period. All isolates were resistant to cephalosporins and quinolones but susceptible to carbapenems, amikacin and nitrofurantoin. Prior antibiotic treatment with more than two antibiotic families (OR=6.86; 95%CI 1.06-157.70; p=0.028), recurrent symptomatic UTIs (OR=5.60; 95%CI 1.88-17.87; p=0.001) and previous hospitalization (OR=5.06; 95%CI 1.64-17.69; p=0.002) were significant risk factors. Sixteen isolates harbored the beta-lactamase (bla)CTX-M-15 gene and five the blaTEM-1 gene. Conclusions. One of every three patients presented UTIs with ESBLs-producing beta-lactams and fluoroquinolone resistant E. coli. Risk factors and resistance patterns must be taken into account for developing antibiotic use policies in these settings.

Objetivo. Evaluar los factores de riesgo en infecciones de vías urinarias (IVUs) causadas por E. coli productora de Beta-Lactamasas de espectro extendido (BLEEs) y caracterizar las BLEEs. Material y métodos. Estudio de casos y controles en pacientes consecutivos con IVUs causadas por E. coli productoras o no de BLEEs en un hospital de referencia. Resultados. E. coli productora de BLEEs se aisló en 22/70 (31%) pacientes con IVUs por E. coli durante un periodo de tres meses. Todos los aislamientos fueron resistentes a cefalosporinas y quinolonas, pero susceptibles a carbapenemes, amikacina y nitrofurantoina. Factores de riesgo significativos incluyeron tratamiento previo con más de dos familias de antibióticos (OR=6.86; IC95% 1.06-157.70; p=0.028), IVUs sintomáticas recurrentes (OR=5.60; IC95% 1.88-17.87; p=0.001) y hospitalizaciones previas (OR=5.06; IC95% 1.64-17.69; p=0.002). Dieciséis aislamientos presentaron el gen betalactamasas (bla)CTX-M-15 y cinco el gen blaTEM-1. Conclusiones. Uno de cada tres pacientes presentó IVU con E. coli resistente a beta-lactámicos, fluoroquinolonas y productora de BLEEs. En estos casos, los factores de riesgo y patrones de resistencia deberían tomarse en cuenta para recomendar tratamiento.

ABSTRACT: Introduction: Enteric bacteria causing nosocomial infections are often resistant to third-generation cephalosporins due to the production of extended-spectrum β-lactamases (ESBLs). Objective: To describe and characterize the ESBLs pattern present in Klebsiella pneumoniae and Serratia marcescens strains, isolated as causative of nosocomial sepsis in pediatric patients at Instituto Nacional de Pediatría (National Institute of Pediatrics). Material and methods: We analyzed 94 strains of K. pneumoniae and 7 of S. marcescens isolated from clinical specimens from 2002-2005, causative of sepsis in a children's hospital. We evaluated antibiotic susceptibility and detection of ESBL phenotypes by disk diffusion methods; ceftazidime-resistant isolates were further characterized by pulsed field gel electrophoresis (PFGE); and ESBLs were phenotypically and genotypically characterized by isoelectric focusing, polymerase chain reaction (PCR) and sequencing. We also assed for presence of conjuga-tive plasmids bearing the ESBL gene. Results: 51/94 (54%) of K. pneumoniae isolates, and 5/7 (71%) of S. marcescens isolates were resistant to ceftazidime; all carried a blaSHV5 gene. All K. pneumoniae isolates had a distinct PFGE profile, yet all carried a -48-Kb plasmid, that was conjugatively transferable to an Escherichia coli receptor, which expressed the resistance phenotype. On the other hand, all S. marcescens isolates had a similar PFGE profile, were unable to transfer the ceftazidime-resistance phenotype, and were isolated from the same ward in a short time-span suggesting an outbreak. Conclusions: The overall prevalence of ESBL-producing enteric bacteria in this hospital is high but similar to other Latin American reports. The sulfhydryl variable-5 (SHV-5) ESBL gene appears to reside in a highly mobile plasmid, capable of spreading among different K. pneumoniae clones and perhaps even to S. marcescens.

Objective. To assess the risks factors for urinary tract infections (UTIs) caused by Extended-Spectrum Beta-Lactamases (ESBLs)-producing E. coli and the molecular characterization of ESBLs. Materials and methods. A case-control study was performed to identify risk factors in consecutively recruited patients with UTIs caused by ESBLs or non-ESBLs-producing E. coli in a tertiary hospital in Mexico. Results. ESBLs-producing E. coli were isolated from 22/70 (31%) patients with E. coli UTIs over a three month period. All isolates were resistant to cephalosporins and quinolones but susceptible to carbapenems, amikacin and nitrofurantoin. Prior antibiotic treatment with more than two antibiotic families (OR=6.86; 95%CI 1.06-157.70; p=0.028), recurrent symptomatic UTIs (OR=5.60; 95%CI 1.88-17.87; p=0.001) and previous hospitalization (OR=5.06; 95%CI 1.64-17.69; p=0.002) were significant risk factors. Sixteen isolates harbored the beta-lactamase (bla)CTX-M-15 gene and five the blaTEM-1 gene. Conclusions. One of every three patients presented UTIs with ESBLs-producing beta-lactams and fluoroquinolone resistant E. coli. Risk factors and resistance patterns must be taken into account for developing antibiotic use policies in these settings.

Objetivo. Evaluar los factores de riesgo en infecciones de vías urinarias (IVUs) causadas por E. coli productora de Beta-Lactamasas de espectro extendido (BLEEs) y caracterizar las BLEEs. Material y métodos. Estudio de casos y controles en pacientes consecutivos con IVUs causadas por E. coli productoras o no de BLEEs en un hospital de referencia. Resultados. E. coli productora de BLEEs se aisló en 22/70 (31%) pacientes con IVUs por E. coli durante un periodo de tres meses. Todos los aislamientos fueron resistentes a cefalosporinas y quinolonas, pero susceptibles a carbapenemes, amikacina y nitrofurantoina. Factores de riesgo significativos incluyeron tratamiento previo con más de dos familias de antibióticos (OR=6.86; IC95% 1.06-157.70; p=0.028), IVUs sintomáticas recurrentes (OR=5.60; IC95% 1.88-17.87; p=0.001) y hospitalizaciones previas (OR=5.06; IC95% 1.64-17.69; p=0.002). Dieciséis aislamientos presentaron el gen betalactamasas (bla)CTX-M-15 y cinco el gen blaTEM-1. Conclusiones. Uno de cada tres pacientes presentó IVU con E. coli resistente a beta-lactámicos, fluoroquinolonas y productora de BLEEs. En estos casos, los factores de riesgo y patrones de resistencia deberían tomarse en cuenta para recomendar tratamiento.